PRESS RELEASE published on 05/05/2026 at 07:30, 2 months 28 days ago Inside Information / Other news releases Sensorion announces participation in ASGCT Annual Meeting to present gene therapy treatments for hereditary deafness Gene Therapy Innovative Treatments Sensorion ASGCT Annual Meeting Hereditary Deafness
BRIEF published on 04/21/2026 at 07:35, 3 months 11 days ago Sensorion is preparing for its Annual General Meeting Shareholders General Assembly Preparatory Documents Remote Voting Sensory
PRESS RELEASE published on 04/21/2026 at 07:30, 3 months 11 days ago Terms of availability of the preparatory documents for the GM Sensorion provides Preliminary Documents for the Combined Shareholders' General Meeting of May 11, 2026. Shareholders urged to participate in a critical meeting addressing new therapies for hearing loss disorders Biotechnology Shareholders' Meeting Gene Therapy Sensorion Hearing Loss
BRIEF published on 03/23/2026 at 07:35, 4 months 10 days ago Sensorion continues its development in gene therapy for deafness Gene Therapy Congenital Deafness Audiogene Sense-501 Sense-601
BRIEF published on 03/23/2026 at 07:35, 4 months 10 days ago Sensorion Updates on Audiogene Trial and Advances GJB2-GT Clinical Trials Gene Therapy Sensorion Hearing Loss SENS-601
BRIEF published on 03/18/2026 at 07:35, 4 months 15 days ago Sensorion Reports 2025 Results and Corporate Updates Financial Results Gene Therapy Sensorion Hearing Loss Sanofi Investment
PRESS RELEASE published on 03/18/2026 at 07:30, 4 months 15 days ago Inside Information / News release on accounts, results Sensorion reports full-year 2025 results, provides corporate update, and announces release of annual report. Key milestones in gene therapies for hearing loss. Financial highlights and future expectations highlighted Financial Highlights Full-year Results Sensorion Gene Therapies Future Milestones
BRIEF published on 02/17/2026 at 07:35, 5 months 13 days ago Sensorion announces changes in its management Change Of Direction Sensory Auditory Therapy Sanofi Financing Medical Pipeline
BRIEF published on 02/17/2026 at 07:35, 5 months 13 days ago Leadership Transition at Sensorion amid Strategic Focus on Hearing Loss Therapies Biotechnology Gene Therapy Leadership Change Sensorion Hearing Loss
PRESS RELEASE published on 02/17/2026 at 07:30, 5 months 13 days ago Inside Information / Other news releases Sensorion announces Nawal Ouzren stepping down as CEO for personal reasons. Amit Munshi to serve as Interim CEO. Sanofi-led financing for pipeline assets Leadership Changes Sanofi Sensorion Amit Munshi Nawal Ouzren
Published on 08/01/2026 at 01:20, 1 day 19 hours ago Gamma Resources Announces $880,000 Private Placement with Full Warrant Coverage
Published on 08/01/2026 at 01:15, 1 day 19 hours ago Clean Air Metals and Fiore-Backed Springbok Ventures Announce Strategic Business Combination
Published on 08/01/2026 at 00:30, 1 day 19 hours ago Battery X Metals Announces Amendment to Corporate Awareness Engagement
Published on 07/31/2026 at 23:20, 1 day 21 hours ago Pentagon I Capital Corp. Announces Conditional Acceptance of Qualifying Transaction with Prospectiva Resources Ltd.
Published on 08/02/2026 at 08:15, 12 hours 8 minutes ago Holcim signs agreement to divest its business in the Philippines
Published on 08/01/2026 at 16:35, 1 day 3 hours ago HIZENERGY Enters Global Top Tier with BloombergNEF Tier 1 Listing
Published on 07/31/2026 at 19:55, 2 days ago EQS-Adhoc: ABO Energy GmbH & Co. KGaA Reaches Agreement with Financing Partners on Extension of Standstill Agreement and Continuation of Restructuring Process
Published on 07/31/2026 at 19:05, 2 days 1 hour ago Eurobattery Minerals presents the Q2 report for 2026 as the Company accelerates the development of the San Juan tungsten project
Published on 07/31/2026 at 21:00, 1 day 23 hours ago Carrefour completes the sale of its minority stake in CarrefourSA in Turkey to Yeni Mağazacılık A.Ş., operator of the A101 retail chain and controlled by the Aydın Group
Published on 07/31/2026 at 19:13, 2 days 1 hour ago Covivio - Information on Treasury shares transactions between July 29th, 2026 and July 31st, 2026
